top of page
Balversa
HCP
It's time to take a different direction
Darian Momanaee (CW) | Kaio Mendes (AD)
Balversa just got a new indication, to treat advanced tumors agnostically. This means patients have a new therapy further into treatment.
How do we tell healthcare professionals about this new indication? We update the existing campaign and tell a story from unmet need through efficacy.
Message Platform
Unmet need: Current standard-of-care treatments are limited for patients with FGFR+ solid cancers.
Testing: Appropriate testing for FGFR alterations helps identify patients who may benefit from Balversa.
Trial Design: Study R is the largest tumor-agnostic trial of a targeted therapy to date.
Patient Population: Balversa was studied in a broad range of patients with FGFR+ tumors.
Efficacy: Balversa delivered a response rate of 29% across 14 distinct FGFR+ tumor types.
Safety: Less than 10% of patients experienced adverse effects that led to treatment discontinuation.
Dosing: Balversa is the only oral pan-tumor treatment available for FGFR+ solid tumors.
Summary: For your previously treated patients with solid tumors test for FGFR+, choose Balversa.
Summary: Balversa is now approved for your patients with FGFR+ solid tumors and delivers clinically meaningful durable responses.
Campaign Concepting
Insight: When HCPs discover FGFR alterations in their patients with solid tumors, they've found more than a biomarker—months of moments for their patients.
Insight: When HCPs don't perform early NGS testing, they can't see the benefits of a targeted
tumor-agnostic treatment.
Let's show them the connection between testing and Balversa.
bottom of page